Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma

(E-pub Ahead of Print)

Author(s): Parveen Bansal, Deepak K. Dwivedi, Deepa Hatwal, Priyanka Sharma, Vikas Gupta, Suresh Goyal, Mukesh Maithani*

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Become EABM
Become Reviewer
Call for Editor


Urothelial carcinoma has become the ninth most common malignancy in the world. Since the 1980s, diverse studies and treatment methods came out with their possible effects along with certain limitations. Initially, platinum chemotherapy was considered as first-line treatment of the disease. Although it was proved to be effective initially, the most number of cases reported the reoccurrence of the disease. Furthermore, aberrant ligand- dependent and constitutive ligand-independent fibroblast growth factor receptor (FGFR) signaling has been reported in a large number of solid tumors, including urothelial carcinoma that became the basis for FGFR inhibition for the treatment of the disease. Erdafitinib is a pan-FGFR inhibitor that was recently approved in the USA for the treatment of locally advanced or metastatic FGFR3 or FGFR2 urothelial carcinoma. The drug is also being investigated as a treatment for other cancers, including cholangiocarcinoma, liver cancer, non-small cell lung cancer, prostate cancer, lymphoma cancer and oesophageal cancer. This article summarizes the various treatments that evolved for bladder cancer till now, a brief description of the biology of FGFR inhibition, clinical pharmacology, and various clinical trials of erdafitinib.

Keywords: Urinary bladder neoplasm , chemotherapy adjuvant , fibroblast growth factor , pharmacokinetics , pharmacodynamics , clinical trials, erdafitinib.

Rights & PermissionsPrintExport Cite as

Article Details

Published on: 20 January, 2021
(E-pub Ahead of Print)
DOI: 10.2174/1871520621666210121093852
Price: $95

Article Metrics

PDF: 247